Lumbosacral Radicular Pain Management Market Report 2026

The lumbosacral radicular pain management market size has grown strongly in recent years. It will grow from $0.9 billion in 2025 to $0.95 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising cases of spinal disc disorders, reliance on pharmacological pain relief, hospital-based pain treatment, increasing orthopedic consultations, growth of physical therapy services.

The lumbosacral radicular pain management market size is expected to see strong growth in the next few years. It will grow to $1.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population growth, demand for long-term pain management, adoption of non-invasive therapies, home-based rehabilitation expansion, advancements in pain diagnostics. Major trends in the forecast period include growing preference for multimodal pain management, increased adoption of non-opioid therapies, expansion of physical therapy-based interventions, rising demand for minimally invasive pain treatments, integration of personalized pain management plans.

The rising prevalence of back pain disorders is expected to drive the growth of the lumbosacral radicular pain management market in the coming years. Back pain disorders encompass a variety of conditions affecting the spine, muscles, or nerves in the back, leading to discomfort and pain. Their increasing prevalence is largely attributed to sedentary lifestyles, which weaken back muscles, contribute to poor posture, and cause persistent pain. Lumbosacral radicular pain management focuses on alleviating nerve root irritation in the lower back, reducing pain and inflammation, restoring mobility, and improving quality of life. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, back problems were the third leading contributor to disease burden in Australia in 2023, accounting for 4.3% of the nation’s total disease burden. Therefore, the rising prevalence of back pain disorders is driving the lumbosacral radicular pain management market.

Major companies in the lumbosacral radicular pain management market are focusing on advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide non-opioid options for long-lasting pain relief. An investigational oral NaV1.8 pain signal inhibitor is a trial-stage medication targeting the NaV1.8 sodium channel, a critical pathway for transmitting pain through sensory nerves. For example, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, reported results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in pain from baseline in the suzetrigine group. The drug was generally well tolerated, with no serious adverse events, and Vertex plans to refine its Phase 3 trials to account for placebo effects and further evaluate efficacy.

In October 2024, Stryker Corporation, a US-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. Through this acquisition, Stryker aims to strengthen its interventional pain management portfolio, expand its presence in ambulatory surgery centers, and enhance its offerings in minimally invasive treatments for chronic lower back pain. Vertos Medical Inc. is a US-based company specializing in interventional solutions for minimally invasive procedures to treat lumbar spinal stenosis.

Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lumbosacral radicular pain management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the lumbosacral radicular pain management market by increasing the cost of analgesic drugs, topical formulations, physical therapy equipment, and therapeutic consumables. Retail and hospital pharmacy segments are most affected, especially in North America where imported APIs and medical supplies are widely used. Patients face higher treatment costs for long-term pain control. However, tariffs are encouraging domestic drug formulation and physical therapy equipment manufacturing, improving supply stability.

The lumbosacral radicular pain management market research report is one of a series of new reports that provides lumbosacral radicular pain management market statistics, including lumbosacral radicular pain management industry global market size, regional shares, competitors with a lumbosacral radicular pain management market share, detailed lumbosacral radicular pain management market segments, market trends and opportunities, and any further data you may need to thrive in the lumbosacral radicular pain management industry. This lumbosacral radicular pain management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lumbosacral radicular pain management refers to a comprehensive approach for diagnosing, treating, and alleviating pain caused by irritation or compression of the spinal nerve roots in the lumbosacral region (lower back and sacral area). It is commonly linked to conditions such as herniated discs, spinal stenosis, or degenerative disc disease. Management aims to reduce inflammation, relieve pressure on affected nerves, and support functional recovery, with the primary goal of improving mobility, minimizing pain, and enhancing overall quality of life.

The main medications used in lumbosacral radicular pain management include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, anticonvulsants, and steroids. NSAIDs are commonly used as a first-line treatment to reduce inflammation and relieve pain by inhibiting inflammation-causing enzymes. Management also involves physical therapies such as manual therapy, exercise therapy, electrotherapy, thermal therapy, and hydrotherapy. Medications are administered through oral and topical routes and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies for use by various end users.

The lumbosacral radicular pain management market consists of revenues earned by entities by providing services such as psychological therapy, surgical intervention, chiropractic care, and pharmacological management. The market value includes the value of related goods sold by the service provider or included within the service offering. The lumbosacral radicular pain management market includes sales of muscle relaxants, epidural steroid injections, and nerve blocks. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.